<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04681820</url>
  </required_header>
  <id_info>
    <org_study_id>HS-2020-07WH</org_study_id>
    <nct_id>NCT04681820</nct_id>
  </id_info>
  <brief_title>Evaluating Efficacy and Safety of Flumatinib Versus Nilotinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) Without Optimal Response (Warning,Failure) to Imatinib or Dasatinib</brief_title>
  <official_title>Evaluating Efficacy and Safety of Flumatinib Versus Nilotinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) Without Optimal Response (Warning or Failure) to Imatinib or Dasatinib: A Prospective, Multicenter, Pragmatic Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wuhan Union Hospital, China</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Imatinib has revolutionized the treatment of chronic myeloid leukemia (CML) and is the&#xD;
      current standard of care in the treatment of patients with newly diagnosed CML. However,&#xD;
      about 30% of patients still show drug resistance or disease progression. Currently, the most&#xD;
      widely studied mechanism of TKI resistance in CML patients is mutations in the ABL kinase&#xD;
      region. So far, more than 100 kinase domain mutations have been found in disease progression&#xD;
      and imatinib resistance. It is estimated that more than 25% of CML patients will change TKI&#xD;
      at least once in their lifetime due to drug resistance or intolerance. The 2020 edition of&#xD;
      the &quot;Guidelines for the Diagnosis and Treatment of Chronic Myelogenous Leukemia in China&quot;&#xD;
      proposes that patients with F317L/V/I/C, V299L and T315A mutations are more likely to obtain&#xD;
      clinical efficacy by switching to the second-generation TKI nilotinib; patients with Y253H,&#xD;
      E255K/V and F359C/V/I mutations are more likely to obtain clinical efficacy by switching to&#xD;
      the second-generation TKI dasatinib; patients with T315I mutations are resistant to both&#xD;
      nilotinib and dasatinib. Flumatinib has been shown to be a more potent inhibitor of BCR-ABL1&#xD;
      tyrosine kinase than imatinib. In vitro studies, it has shown that flumatinib inhibits&#xD;
      wild-type and common BCR-ABL mutations(Q252H, V299L, F317L/I, M351T, H396P, etc.) more&#xD;
      potently, and the anti-mutation spectrum of flumatinib is similar to nilotinib. Therefore,&#xD;
      this study is designed to provide clearer guidance for patients with suboptimal response or&#xD;
      failure in the treatment of TKI as well as those who have specific ABL kinase domain&#xD;
      mutations during CML treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Major molecular response rate at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Major molecular response is defined as ≤ 0.1% BCR-ABL/ABL% by international scale</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>CML-CP; Mutation;Suboptimal Response or Failure in TKI</condition>
  <arm_group>
    <arm_group_label>flumatinib</arm_group_label>
    <description>flumatinib 600mg QD, fasting administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nilotinib</arm_group_label>
    <description>nilotinib 400mg BID, fasting administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flumatinib</intervention_name>
    <description>Flumatinib mesylate tablets 600mg qd for 24 months</description>
    <arm_group_label>flumatinib</arm_group_label>
    <arm_group_label>nilotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib</intervention_name>
    <description>Nilotinib Capsules 400mg bid for 24 months</description>
    <arm_group_label>flumatinib</arm_group_label>
    <arm_group_label>nilotinib</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        CML-CP patients without optimal response(warning or failure) treated with imatinib or&#xD;
        dasatinib&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients ≥18 years of age;&#xD;
&#xD;
          2. CML-CP patients when enrolled&#xD;
&#xD;
             Definition of diagnosis:&#xD;
&#xD;
             Bone marrow cytogenetic confirmation of Philadelphia chromosome of t (9;22)&#xD;
             translocations and/or the presence of P210 BCR-ABL1 transcripts via molecular&#xD;
             assessment;&#xD;
&#xD;
             Documented chronic phase CML will meet all the criteria defined as:&#xD;
&#xD;
             &lt; 15% blasts in peripheral blood and bone marrow &lt; 30% blasts plus promyelocytes in&#xD;
             peripheral blood and bone marrow &lt; 20% basophils in the peripheral blood&#xD;
&#xD;
             ≥ 100 x 109/L (≥ 100,000/mm3) platelets No evidence of extramedullary leukemic&#xD;
             involvement, with the exception of hepatosplenomegaly&#xD;
&#xD;
          3. CML-CP patients without optimal response(warning or failure) when treated with&#xD;
             imatinib or dasatinib.&#xD;
&#xD;
          4. Female patients of childbearing potential must have a negative serum pregnancy test;&#xD;
&#xD;
          5. Ability to provide written informed consent prior to any study related screening&#xD;
             procedures being performed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Treatment with other tyrosine kinase inhibitor(s) except imatinib and dasatinib prior&#xD;
             to study entry;&#xD;
&#xD;
          2. With any mutations as follows :T315I、Y253F/H、E255K/V、F359C/V/I (if there are any other&#xD;
             mutations,at physicians' discretion );&#xD;
&#xD;
          3. Entry into another therapeutic clinical trial;&#xD;
&#xD;
          4. Concomitant diseases that, according to the investigator's judgment, pose a serious&#xD;
             risk to the patient's safety or completion of the study;&#xD;
&#xD;
          5. History of neurological or psychiatric disorders, including epilepsy or dementia;&#xD;
&#xD;
          6. Major surgery within 4 weeks prior to Day 1 of study;&#xD;
&#xD;
          7. Patients with another primary malignancy,unless the other primary malignancy is&#xD;
             currently stable or does not need active intervention;&#xD;
&#xD;
          8. Women of reproductive age or men who are unable to use adequate methods of&#xD;
             contraception, including women who are pregnant or breastfeeding;&#xD;
&#xD;
          9. ECOG≥3;&#xD;
&#xD;
         10. Patients who are unable to compliance with study or follow-up procedures;&#xD;
&#xD;
         11. Allergic to any of the components in this trial;&#xD;
&#xD;
         12. Not appropriate to attend this trial judged by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Weiming Li</last_name>
    <phone>13098815546</phone>
    <email>liweiming202012@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Weiming Li</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Wei Li</last_name>
      <phone>13098815546</phone>
      <email>liweiming202012@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 18, 2020</study_first_submitted>
  <study_first_submitted_qc>December 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>May 31, 2021</last_update_submitted>
  <last_update_submitted_qc>May 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wuhan Union Hospital, China</investigator_affiliation>
    <investigator_full_name>Weiming Li</investigator_full_name>
    <investigator_title>chief physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HH-GV-678</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

